Stellon A J, Hegarty J E, Portmann B, Williams R
Lancet. 1985 Mar 23;1(8430):668-70. doi: 10.1016/s0140-6736(85)91329-7.
To assess the value of azathioprine in the maintenance therapy of autoimmune chronic active hepatitis a controlled trial of azathioprine withdrawal was carried out in 50 patients who had been maintained in remission on a combination of azathioprine and prednisolone. The patients were randomly allocated to remain on combination therapy (23) or to discontinue azathioprine (27). These 2 groups were comparable at the start of the study. Over a follow-up period of up to 3 years, biochemical and histological relapse occurred in 8 patients in the azathioprine-withdrawal group but in only 1 patient in the combination-therapy group. Cumulative probability of relapse was 32% among the patients in the withdrawal group, compared with 6.0% for those in the combination group.
为评估硫唑嘌呤在自身免疫性慢性活动性肝炎维持治疗中的价值，对50例在硫唑嘌呤与泼尼松龙联合治疗下病情缓解的患者进行了硫唑嘌呤撤药对照试验。患者被随机分配继续联合治疗（23例）或停用硫唑嘌呤（27例）。这两组在研究开始时具有可比性。在长达3年的随访期内，硫唑嘌呤撤药组有8例患者出现生化和组织学复发，而联合治疗组仅有1例患者复发。撤药组患者的累积复发概率为32%，而联合治疗组为6.0%。
